Cyagen delivers a full-service partnership that extends from study design to data interpretation:

Dedicated Ph.D. project manager and technical specialists for real-time progress updates

In-house downstream services – histopathology, flow cytometry, multi-omics (RNA-Seq, proteomics), in vivo imaging, and drug-efficacy testing

Custom assay development & data analysis – tailored to immuno-oncology endpoints

Regulatory-ready documentation – health certificates, QC reports, and SOPs compatible with GLP submissions

This integrated support enables researchers to accelerate discovery while relying on Cyagen for model generation, colony management, and comprehensive phenotyping under one roof.

Our QC framework combines:

Genotype confirmation – PCR/long-range PCR, Sanger sequencing, and copy-number checks for each founder and every breeding generation.

Microbiological surveillance – SPF housing, quarterly sentinel panels, and mycoplasma/fecal PCR screens.

Environmental controls – IVC/EVC caging, HEPA-filtered airflow, and automated temperature/humidity logging.

Comprehensive records – digital pedigree tracking and colony health logs accessible to clients upon request.

These multilayer safeguards minimize drift, adventitious infection, and phenotypic variability.

Using our proprietary TurboKnockout® ES-cell platform, most custom germline spontaneous-tumor founders are delivered in 6–8 months, with 100 % guaranteed GLT or your fee is refunded. Larger knock-ins, dual-allele designs, or inducible systems may add 2–4 weeks, but the GLT guarantee remains.

Yes. Cyagen’s spontaneous-tumor portfolio includes KRAS-driven PDAC strains such as LSL-Kras G12D/G12C mice and allied Cre-driver combinations. These models reproduce hallmark oncogenic mutations (e.g., KRAS-G12D, G12C) and develop in-situ tumors within an intact, immunocompetent C57BL/6 microenvironment—capturing the dense stroma and immune contexture characteristic of human PDAC. Custom syngeneic or multi-allelic PDAC models can also be generated on request.

Absolutely. Each catalogued spontaneous tumor line is delivered with a data package that typically includes survival curves, gross-pathology images, H&E/IHC staining, and, where available, transcriptomic readouts. For example, our MYC-driven liver tumor model page shows survival data and histopathology images that validate tumor onset and progression. Additional assays (flow cytometry, RNA-Seq, etc.) can be commissioned through our in-house phenotype analysis platform.